Mouse anti-SARS-CoV-2 S Monoclonal Antibody

Function

Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes

Subcellular Location

Virion membrane (Single-pass type I membrane protein); Host endoplasmic reticulum-Golgi intermediate compartment membrane (Single-pass type I membrane protein); Host cell membrane (Single-pass type I membrane protein)

Subunit

Binds to host ACE2 (PubMed:32075877, PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175, PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a polybasic C-terminal sequence on S1 that binds to host Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293, PubMed:33082294). Interacts with host integrin alpha-5/beta-1 (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1 (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-terminus with M protein (PubMed:33229438). May interact (via N-terminus) with host bilirubin and biliverdin, thereby preventing antibody binding to the SARS-CoV-2 spike NTD via an allosteric mechanism (PubMed:33888467). May interact with host LRRC15, thereby allowing attachment to host cells (PubMed:36735681)

• Wu F. et al. A new coronavirus associated with human respiratory disease in China. — Nature (2020)
• Hoffmann M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. — Cell (2020)
• Hoffmann M. et al. A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential for infection of human lung cells. — Mol. Cell (2020)
• Watanabe Y. et al. Site-specific glycan analysis of the SARS-CoV-2 spike. — Science (2020)
• Shajahan A. et al. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. — Glycobiology (2020)
• Isabel S. et al. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. — Sci. Rep. (2020)
• Korber B. et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. — Cell (2020)
• Turonova B. et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. — Science (2020)